AI boosts kidney drug dosing: hope for membranous nephropathy patients

NCT ID NCT06341205

Recruiting now Disease control Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether artificial intelligence can help doctors personalize rituximab doses for people with membranous nephropathy, an autoimmune kidney disease. About 120 adults with active disease will receive either standard rituximab or AI-guided dosing to keep drug levels high enough. The goal is to see if personalized dosing leads to more remissions after 6 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MEMBRANOUS NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

membranous glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MEMBRANOUS NEPHROPATHY

Contacts and locations

Locations

AP-HM - Hôpital de la Conception
RECRUITING

Marseille, France
AP-HP - Hôpital Européen Georges Pompidou
RECRUITING

Paris, France
AP-HP - Hôpital H. Mondor
RECRUITING

Créteil, France
AP-HP - Hôpital Necker
RECRUITING

Paris, France
CH de Valenciennes
RECRUITING

Valenciennes, France
CHRU de TOURS - Hôpital Bretonneau
RECRUITING

Tours, France
CHU de BESANCON
RECRUITING

Besançon, France
CHU de BORDEAUX - Hôpital Pellegrin
RECRUITING

Bordeaux, France
CHU de CAEN
RECRUITING

Caen, France
CHU de NICE
RECRUITING

Nice, France
CHU de Nîmes - Hôpital CAREMEAU
RECRUITING

Nîmes, France
CHU de TOULOUSE - Hôpital Rangueil
RECRUITING

Toulouse, France
HCL - Hôpital E. Herriot
RECRUITING

Lyon, France
Hôpital Tenon
NOT_YET_RECRUITING

Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.